CytoMed Therapeutics Ltd (GDTC) stock
GDTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.78+0.01 (+1.18%)
Close on Nov 17, 2026Market cap $9.26MP/E –Yield –
Earnings
CytoMed Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of CytoMed Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
CytoMed Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When CytoMed Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases CytoMed Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
See a number that looks wrong?